Delving into the Latest Updates on LN2222 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

LN2222

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication

Constipation

Inactive Indication-

Originator Organization

Shandong New Time Pharmaceutical Co. Ltd.

Active Organization

Shandong New Time Pharmaceutical Co. Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

To investigate the safety, tolerability, and pharmacokinetic characteristics of a single dose of LN2222 injection in healthy adult study participants in China, and to compare its bioavailability with that of a control drug (prucalopride succinate tablets), to provide a theoretical basis for dose selection in subsequent studies.

Start Date22 Dec 2025

Sponsor / Collaborator

Shandong New Time Pharmaceutical Co. Ltd.

100 Clinical Results associated with LN2222

Login to view more data

100 Translational Medicine associated with LN2222

Login to view more data

100 Patents (Medical) associated with LN2222

Login to view more data

100 Deals associated with LN2222

Login to view more data